Sernova Biotherapeutics Inc
SVA
Company Profile
Business description
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
Contact
RPO Central Parkway
PO Box 29592
MississaugaONL5A 4H2
CANT: +1 877 299-4603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
8
Stocks News & Analysis
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
stocks
Chart of the Week: Booming mined commodity prices see little value on offer
Iran War disruptions drive thermal coal and aluminum prices higher but value to be found in other pockets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.60 | 65.10 | -0.73% |
| CAC 40 | 8,190.54 | 17.35 | -0.21% |
| DAX 40 | 25,069.56 | 108.24 | -0.43% |
| Dow JONES (US) | 50,647.59 | 3.31 | 0.01% |
| FTSE 100 | 10,422.31 | 82.70 | -0.79% |
| HKSE | 25,006.16 | 322.07 | -1.27% |
| NASDAQ | 26,819.37 | 144.63 | 0.54% |
| Nikkei 225 | 64,693.12 | 306.29 | -0.47% |
| NZX 50 Index | 13,206.11 | 21.70 | -0.16% |
| S&P 500 | 7,553.34 | 32.98 | 0.44% |
| S&P/ASX 200 | 8,592.90 | 61.60 | -0.71% |
| SSE Composite Index | 4,098.64 | 4.91 | 0.12% |